Ascendis Pharma A/S reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was EUR 15.29 million compared to EUR 1.11 million a year ago. Net loss was EUR 168.96 million compared to EUR 80.35 million a year ago. Basic loss per share from continuing operations was EUR 3.03 compared to EUR 1.47 a year ago.
For the nine months, sales was EUR 28.28 million compared to EUR 2.88 million a year ago. Net loss was EUR 375.78 million compared to EUR 277.52 million a year ago. Basic loss per share from continuing operations was EUR 6.7 compared to EUR 5.13 a year ago.